BioCardia's CardiAMP Heart Failure Trial Echocardiography Data Accepted for Late Breaking Presentation
BCDA sits 20% above its 52-week low of $1.
Summary
BioCardia announced that echocardiography data from its CardiAMP Cell Therapy for heart failure trial has been accepted for a Late Breaking Clinical Trial Oral Presentation at the upcoming THT Meeting.
Key Events · Product Development and Regulatory · BCDA
-
Late Breaking Presentation Acceptance
Echocardiography data from the CardiAMP Cell Therapy for heart failure trial has been accepted for a Late Breaking Clinical Trial Oral Presentation at the Technology and Heart Failure Therapeutics (THT) Meeting.
-
Presentation Details
The presentation, titled 'Autologous Cell Therapy May Curb Pathological Ventricular Remodeling in Chronic Ischemic HFrEF Patients Selected for Favorable Cell Characteristics - Late Breaking Echocardiography Results from the CardiAMP HF trial,' will be made by Dr. Amish Raval on March 2, 2026.
-
FDA Breakthrough Designation
The CardiAMP Cell Therapy, which uses a patient's own bone marrow cells, has previously been granted FDA Breakthrough designation, highlighting its potential to address unmet medical needs.
Analysis · BCDA · Life Sciences
BioCardia, a micro-cap company, announced the acceptance of echocardiography data from its CardiAMP Cell Therapy for heart failure for a Late Breaking Clinical Trial Oral Presentation. This is a significant positive development as 'Late Breaking' presentations are reserved for important, new, and impactful clinical findings. The CardiAMP Cell Therapy already holds FDA Breakthrough designation, underscoring its potential. The upcoming presentation provides a crucial platform for BioCardia to showcase its clinical progress, which could significantly influence investor sentiment and the company's valuation, especially given its small market capitalization.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 29% of the 1653 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.58%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BCDA was trading at $1.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.8M. The 52-week trading range was $1.00 to $3.20. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.